Date: 2014-02-04
Type of information: Licensing agreement
Compound: homologous recombination technology for research applications
Company: Cellectis (France) Genoway (France)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On February 4, 2014, Cellectis, a French genome engineering specialist, and genOway, a French animal model specialist, have announced an exclusive agreement under which genOway becomes the exclusive provider of Cellectis’ homologous recombination technology for research applications in genetically modified rodents. Cellectis will remain the partner for any other applications, such as bioproduction and therapeutics.
This technology is covered by the WO 90/11354 family of patents owned by Institut Pasteur and exclusively licensed to Cellectis. This generation of high-value genetically modified rodent models, including humanized models, is a major breakthrough. Cellectis’ technology is ranked as the primary tool in genetically modified rodent development by both academic and industrial scientists. Previously, Cellectis was the only source of rights in homologous recombination technology. The solutions genOway now offers respond fully to the needs of the industrial and academic institutions that require a single access to key technologies.
This agreement will enable genOway to exclusively provide academic and industry scientists with complete secure access to Cellectis’ homologous recombination technology for use in rodent models.
Exclusive service provider: genOway will develop and sell research models using homologous recombination technology. Customers of genOway will have complete freedom to operate for their research programs including pharmaceutical research.
Exclusive distributor: Thousands of research models have been developed using homologous recombination technology and are available in either laboratories or repositories. genOway plans to enable scientists to access these resources with the necessary rights.
Exclusive sublicensing rights: A significant proportion of scientists are using models developed using homologous recombination technology with no rights to do so; either because the models were created by in-house facilities or because they were purchased from transgenic companies that had no rights to transfer freedom to operate to the end-user. genOway will now license the required freedom to operate (for past and/or future use) to the end-users. genOway and Cellectis are strongly committed to enabling scientists to benefit from this technology and to prohibiting unauthorized use.
Financial terms: Financial details were not disclosed.
Latest news:
